Sanofi India Ltd - 500674 - Statement Of Investor Complaints For The Quarter Ended September 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 1890 Name of the Signatory :- Radhika ShahDesignation :- Company Secretary and Compliance Officer Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate Sanofi India Ltd - 500674 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Link Intime India Private Limited, Registrar and Share Transfer Agent (RTA) of the Company has provided the enclosed certificate for the quarter ended 30th September 2022 under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. Sanofi India Ltd - 500674 - Closure of Trading Window
Pursuant to the Company's Code of Conduct to Regulate, Monitor and Report Insider Trading by Designated Persons we would like to inform you that, inter alia, for the purpose of declaration of financial results of the Company, for the quarter and nine months ending 30th September 2022, the trading window of the Company shall remain closed from 1st October 2022 till 48 hours after the announcement of the results to the stock exchanges. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has approved issue of duplicate share certificates requests in lieu of the original share certificates reported lost/misplaced. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate Sanofi India Ltd - 500674 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure) Regulations (LODR) And Company'S Policy Of Determination Of Materiality Of Events Under Regulation 30 Of LODR
The Ministry of Health and Family Welfare, Government of India, has released the revised National List of Essential Medicines (NLEM), 2022. In the coming days, the National Pharmaceutical Pricing Authority will fix the ceiling price for the cost to patients of the products included in this revised list. Since insulin glargine (100 IU/ ml) is now a part of the NLEM 2022 list, our Company's insulin glargine brand Lantus(r) will also be subject to price revision. The potential impact on the Company will be known only after the NPPA releases the prices. Though the price revision is likely to have an impact on sales, the Company does not expect a material impact on the profitability considering the arms-length operating model principle being followed with regard to sourcing of this product from Sanofi Group. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s)